DK158980C - Analogifremgangsmaade til fremstilling af 2,5-bis-(2,2,2-trifluorethoxy)-n-(2-piperidylmethyl)benzamid eller et farmaceutisk acceptabelt syreadditionssalt deraf - Google Patents

Analogifremgangsmaade til fremstilling af 2,5-bis-(2,2,2-trifluorethoxy)-n-(2-piperidylmethyl)benzamid eller et farmaceutisk acceptabelt syreadditionssalt deraf

Info

Publication number
DK158980C
DK158980C DK119675A DK119675A DK158980C DK 158980 C DK158980 C DK 158980C DK 119675 A DK119675 A DK 119675A DK 119675 A DK119675 A DK 119675A DK 158980 C DK158980 C DK 158980C
Authority
DK
Denmark
Prior art keywords
trifluorethoxy
piperidylmethyl
benzamide
analogue
bis
Prior art date
Application number
DK119675A
Other languages
Danish (da)
English (en)
Other versions
DK158980B (da
DK119675A (ja
Inventor
Elden Harris Banitt
William Robert Bronn
Original Assignee
Riker Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riker Laboratories Inc filed Critical Riker Laboratories Inc
Publication of DK119675A publication Critical patent/DK119675A/da
Publication of DK158980B publication Critical patent/DK158980B/da
Application granted granted Critical
Publication of DK158980C publication Critical patent/DK158980C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK119675A 1974-04-01 1975-03-21 Analogifremgangsmaade til fremstilling af 2,5-bis-(2,2,2-trifluorethoxy)-n-(2-piperidylmethyl)benzamid eller et farmaceutisk acceptabelt syreadditionssalt deraf DK158980C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45709974 1974-04-01
US457099A US3900481A (en) 1974-04-01 1974-04-01 Derivatives of pyrrolidine and piperidine

Publications (3)

Publication Number Publication Date
DK119675A DK119675A (ja) 1975-10-02
DK158980B DK158980B (da) 1990-08-13
DK158980C true DK158980C (da) 1991-01-07

Family

ID=23815433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK119675A DK158980C (da) 1974-04-01 1975-03-21 Analogifremgangsmaade til fremstilling af 2,5-bis-(2,2,2-trifluorethoxy)-n-(2-piperidylmethyl)benzamid eller et farmaceutisk acceptabelt syreadditionssalt deraf

Country Status (22)

Country Link
US (1) US3900481A (ja)
JP (2) JPS5827268B2 (ja)
AR (1) AR210990A1 (ja)
BE (1) BE827354A (ja)
CA (1) CA1054602A (ja)
CH (1) CH618425A5 (ja)
CS (1) CS209846B2 (ja)
DE (1) DE2513916C2 (ja)
DK (1) DK158980C (ja)
ES (1) ES435870A1 (ja)
FR (1) FR2265366B1 (ja)
GB (1) GB1508015A (ja)
HU (1) HU169762B (ja)
IE (1) IE41224B1 (ja)
IL (1) IL46967A (ja)
NL (1) NL186633C (ja)
NO (1) NO144262C (ja)
OA (1) OA04912A (ja)
PL (1) PL95576B1 (ja)
SE (1) SE391336B (ja)
SU (1) SU668599A3 (ja)
ZA (1) ZA751040B (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197243A (en) * 1975-04-02 1980-04-08 Yamanouchi Pharmaceutical Co., Ltd. N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives
GB1520584A (en) * 1975-04-02 1978-08-09 Yamanouchi Pharma Co Ltd 2 - alkoxy - 5 substituted benzamide derivatives and their use in pharmaceutical compositions
FI763021A (ja) * 1975-11-03 1977-05-04 Thomae Gmbh Dr K
US4071524A (en) * 1976-11-08 1978-01-31 Riker Laboratories, Inc. Derivatives of urea
US4097481A (en) * 1976-11-08 1978-06-27 Riker Laboratories, Inc. Tertiary amide derivatives of pyrrolidine and piperidine
US4642384A (en) * 1979-03-19 1987-02-10 Riker Laboratories, Inc. Process for the preparation of derivatives of pyrrolidine and piperidine
JPS55143967A (en) * 1979-03-19 1980-11-10 Riker Laboratories Inc Manufacture of 2*55bis*2*2*22trifluoroethoxy** nn*22piperidylmethyl*benzamide
US4617396A (en) * 1979-03-19 1986-10-14 Riker Laboratories, Inc. Process for the preparation of derivatives of piperidine
GB2097000B (en) 1979-03-19 1983-11-30 Riker Laboratories Inc Process for the preparation of 1,4-bis(2,2,2-trifluoroethoxy) benzene
US4684733A (en) * 1979-03-19 1987-08-04 Riker Laboratories, Inc. Process for the preparation of intermediates of derivatives of pyrrolidine and piperidine
US4339587A (en) * 1981-06-08 1982-07-13 Riker Laboratories, Inc. 5-Benzyloxy or 5-hydroxy-2-(2,2,2-trifluoroethoxy)-N-(2-pyridylmethyl)benzamide
US4390716A (en) * 1981-06-08 1983-06-28 Riker Laboratories, Inc. Phenolic derivative
US4452983A (en) * 1981-06-08 1984-06-05 Riker Laboratories, Inc. Phenolic derivative
JPS5970666A (ja) * 1982-10-15 1984-04-21 Kyowa Hakko Kogyo Co Ltd １，４−ジヒドロピリジン誘導体
US4656285A (en) * 1983-11-15 1987-04-07 Riker Laboratories, Inc. Compound 2-acetamidomethyl-6-methoxy-pyridine
US4555573A (en) * 1983-11-15 1985-11-26 Riker Laboratories, Inc. Certain 6-benzamidomethyl-2(1H)-pyridone derivatives
US4599434A (en) * 1983-11-15 1986-07-08 Riker Laboratories, Inc. Cyclopentanone derivatives
US4497954A (en) * 1983-11-15 1985-02-05 Riker Laboratories, Inc. Cyclopentanone derivatives
US4496734A (en) * 1983-11-15 1985-01-29 Riker Laboratories, Inc. Metabolite
NZ219913A (en) * 1986-04-25 1990-08-28 Riker Laboratories Inc Various flecainide derivatives and antibodies raised thereto
DE3786037T2 (de) * 1986-04-25 1993-11-25 Abbott Lab Tracer zur Benutzung in immunologischen Fluoreszenz-Polarisationsverfahren zum Nachweis von Flecainid.
US5336622A (en) * 1986-04-25 1994-08-09 Abbott Laboratories Tracers for use in flecainide fluorescence polarization immunoassay
US4952574A (en) * 1988-09-26 1990-08-28 Riker Laboratories, Inc. Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides
US4938966A (en) * 1988-11-30 1990-07-03 Riker Laboratories, Inc. Controlled release flecainide acetate formulation
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
IL121288A (en) * 1997-07-11 2000-10-31 Finetech Ltd Process and a novel intermediate for the preparation of flecainide
ITMI20011772A1 (it) * 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
EP1500651A1 (en) * 2003-07-25 2005-01-26 Bayer CropScience S.A. N-[2-(2-Pyridinyl)ethyl]benzamide compounds and their use as fungicides
US7196197B2 (en) * 2003-09-17 2007-03-27 Apotex Pharmachem Inc. Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof
EP1918280A1 (en) * 2006-11-06 2008-05-07 "Joint Stock Company Grindeks" Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide and salts thereof
AU2007322033B2 (en) 2006-11-20 2013-07-11 President And Fellows Of Harvard College Methods, compositions, and kits for treating pain and pruritis
JP4946482B2 (ja) 2007-02-08 2012-06-06 船井電機株式会社 緩衝用梱包材及びｔｖ受像機の緩衝用梱包材
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
AU2016301282B2 (en) 2015-08-03 2022-03-17 Children's Medical Center Corporation Charged ion channel blockers and methods for use
US11377422B2 (en) 2019-03-11 2022-07-05 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
AU2020237474A1 (en) 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
SG11202109713PA (en) 2019-03-11 2021-10-28 Nocion Therapeutics Inc Ester substituted ion channel blockers and methods for use
KR20220123381A (ko) 2019-11-06 2022-09-06 녹시온 테라퓨틱스 인코포레이티드 하전된 이온 채널 차단제 및 사용 방법
WO2021091586A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
IL295950A (en) 2020-03-11 2022-10-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
WO2024132080A1 (en) 2022-12-22 2024-06-27 Colonis Pharma Ltd Liquid pharmaceutical composition containing flecainide and process for the preparaton thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6209M (ja) * 1967-04-03 1968-07-29
US3655728A (en) * 1970-07-22 1972-04-11 Riker Laboratories Inc N-(2 - dialkylaminoalkylene)-esters of fluoroalkoxy-substituted aryl carboxylic acid and salts thereof
US3719687A (en) * 1970-07-22 1973-03-06 Riker Laboratories Inc N-(2-dialkylaminoalkylene)amides of 1,1-dihydroperfluoroalkoxy-substituted aryl acids and salts thereof

Also Published As

Publication number Publication date
GB1508015A (en) 1978-04-19
DK158980B (da) 1990-08-13
HU169762B (ja) 1977-02-28
PL95576B1 (pl) 1977-10-31
ES435870A1 (es) 1976-12-16
FR2265366B1 (ja) 1980-01-11
JPS5865268A (ja) 1983-04-18
DE2513916A1 (de) 1975-10-09
BE827354A (fr) 1975-09-29
ZA751040B (en) 1976-01-28
OA04912A (fr) 1980-10-31
JPS5827268B2 (ja) 1983-06-08
AU7957875A (en) 1976-09-30
NL186633B (nl) 1990-08-16
DK119675A (ja) 1975-10-02
US3900481A (en) 1975-08-19
NL186633C (nl) 1991-01-16
FR2265366A1 (ja) 1975-10-24
IL46967A0 (en) 1975-05-22
JPS5858347B2 (ja) 1983-12-24
NO750976L (ja) 1975-10-02
SE7503262L (ja) 1975-10-02
CS209846B2 (en) 1981-12-31
NO144262C (no) 1981-07-29
NO144262B (no) 1981-04-21
JPS50137975A (ja) 1975-11-01
CH618425A5 (ja) 1980-07-31
CA1054602A (en) 1979-05-15
IL46967A (en) 1978-09-29
AR210990A1 (es) 1977-10-14
SE391336B (sv) 1977-02-14
SU668599A3 (ru) 1979-06-15
NL7503389A (nl) 1975-10-03
IE41224L (en) 1975-10-01
IE41224B1 (en) 1979-11-21
DE2513916C2 (de) 1982-12-23

Similar Documents

Publication Publication Date Title
DK158980C (da) Analogifremgangsmaade til fremstilling af 2,5-bis-(2,2,2-trifluorethoxy)-n-(2-piperidylmethyl)benzamid eller et farmaceutisk acceptabelt syreadditionssalt deraf
DK145339C (da) Analogifremgangsmaade til fremstilling af 4-amino-5-hexensyre eller farmaceutisk acceptable salte deraf
DK151623C (da) Analogifremgangsmaade til fremstilling af n-substituerede moranolinderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK149597C (da) Analogifremgangsmaade til fremstilling af calcitoninanaloge hentriaconpeptidderivater eller farmaceutisk acceptable syreadditionssalte eller komplekser deraf
DK151331C (da) Analogifremgangsmaade til fremstilling af 5-pyridinyl-2(1h)-pyridinon-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK148904C (da) Analogifremgangsmaade til fremstilling af analgetisk virksomme enkephalin-analoge pentapeptidamider eller farmaceutisk acceptable, ikke-toxiske syreadditionssalte deraf
DK145376C (da) Analogifremgangsmaade til fremstilling af n-(1'-benzyl-2'-pyrrolidinylmethyl)-benzamider eller syreadditionssalte,kvaternaere ammoniumsalte eller optisk aktive isomere deraf
DK160045C (da) Analogifremgangsmaade til fremstilling af 4-oxo-4h-pyridooe1,2-aaapyrimidiner eller farmaceutisk acceptable syreadditionssalte eller kvaternaere ammoniumsalte deraf
DK149230C (da) Analogifremgangsmaade til fremstilling af 5-benzoyl-6-hydroxy-indan-1-carboxylsyrederivater eller farmaceutisk acceptable salte deraf
DK154950C (da) Analogifremgangsmaade til fremstilling af 1-(benzazolylalkyl)-piperidinderivater eller de farmaceutisk acceptable syreadditionssalte deraf
DK149231C (da) Analogifremgangsmaade til fremstilling af enkephalin-analoge tetrapeptidamider eller syreadditionssalte deraf
DK149625C (da) Analogifremgangsmaade til fremstilling af n-substituerede (8-halogen- eller -trifluormethyl-4-quinolylamino)-benzamider eller et farmaceutiskacceptabelt syreadditionssalt deraf
DK149077C (da) Analogifremgangsmaade til fremstilling af encephalin-analoge pentapeptidamidderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK142544C (da) Analogifremgangsmaade til fremstilling af 2-(n-propargyl-n-phenylamino)-imidazolin-(2)-derivater eller fysiologisk acceptable syreadditionssalte heraf
DK149946C (da) Analogifremgangsmaade til fremstilling af piperidin-derivater af 1,2- eller 1,3-(di-o-n-alkyl)propandiol eller farmaceutisk acceptable syreadditionssalte deraf
DK149841C (da) Analogifremgangsmaade til fremstilling af alfa-fluor-methyl-alfa-aminoalkansyrer eller farmaceutisk acceptable syreadditionssalte deraf
DK155672C (da) Analogifremgangsmaade til fremstilling af aminosyrederivater eller fysiologisk acceptable salte eller optisk aktive isomerer deraf
DK143278C (da) Analogifremgangsmaade til fremstilling af n-(r-tetrahydrofurfuryl)-noroxymorphon eller syreadditionssalte deraf
DK159435C (da) Analogifremgangsmaade til fremstilling af 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)benzoesyrederivater eller et farmaceutisk acceptabelt syreadditionssalt deraf
DK498975A (da) N2-naphthalensulfonyl-l-arginin-derivater og farmaceutisk acceptable syreadditionssalte deraf samt deres anvendelse og fremgangsmade til deres fremstilling
DK384975A (da) Anthelmintisk virksomme 2-carbalkoxyaminobenzimidazolyl-5(6)-sulfonsyrephenylestere samt fremgangsmade til deres fremstilling
DK152211C (da) Analogifremgangsmaade til fremstilling af n-phenyl-n-(4-piperidinyl)-amider eller farmaceutisk acceptable syreadditionssalte deraf.
DK157021C (da) Analogifremgangsmaade til fremstilling af 2,3-polymethylen-4-oxo-4h-pyrido- eller -azepinooe1,2-aaapyrimidiner eller farmaceutisk acceptable syreadditionssalte eller kvaternaere salte deraf
DK146851C (da) Analogifremgangsmaade til fremstilling af benzylaminer eller deres syreadditionssalte af en- eller flerbasiske, fysiologisk acceptable syrer
DK142987C (da) Analogifremgangsmaade til fremstilling af 4-(7-brom-5-methoxy-2-benzofuranyl)-piperidin eller farmaceutisk acceptable syreadditionssalte deraf